News
-
-
-
COMMUNIQUÉ DE PRESSE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer by Jaguar Health, enhancing intellectual property protection. Proof-of-concept studies ongoing for SBS and MVID -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Second Quarter 2024 Financial Results
Jaguar Health, Inc. reports a 16% revenue increase in Q2 2024 for prescription and non-prescription products. Company explores approval pathways for crofelemer in rare diseases, plans commercial launch of Gelclair in October 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Napo Pharmaceuticals announced positive results of studies on crofelemer for chronic refractory diarrhea at the ACG Annual Scientific Meeting. The drug may benefit patients with functional diarrhea and chronic idiopathic diarrhea -
